Cedrus Investments’ Chairman Mr. Rani Jarkas is Invited to Speak at the 121 Tech Investment Conference in Hong Kong on Life Sciences

The Chairman of Cedrus Investments (“Cedrus”), Mr. Rani Jarkas, is invited to speak at the 121 Tech Investment conference to be held on 13th – 14th June 2018 in Hong Kong.

http://www.cedrusinvestments.com/news.html

Advertisements

王雷(Rani Jarkas):“一带一路”倡议将在未来十年内对矿业产生巨大影响 赛德思投资董事长 王雷(Rani Jarkas)

“一带一路”倡议在横跨亚洲中东欧洲非洲的68个国家创造了5万亿美元的基础建设开支和资本合作热潮。大量资金被用于建造港口公路铁路发电站,并且成为例如铁矿原油稀有金属大宗商品消费的持续动力。

据报道, “一带一路”倡议拥有9千亿美元的投资支撑,并有潜力产生约1.2亿吨的原钢需求。一些矿业公司在2017年公布报告所展示的数据则更为乐观,高达1.5亿吨。

赛德思集团董事长王雷Rani Jarkas)在接受美国CNBC财经电视台的采访时表示,“一带一路”倡议目前正处在起步阶段,已经开始为钢铁和铁矿石带来了巨大的市场需求。

借助这一重大发展契机,全球矿业都迎来了巨大的机遇,中国与世界其他矿业公司建立起供给、支持、合作的关系。例如,澳大利亚的矿产业务因得益于幅员辽阔的国土面积,矿业拥有丰富的历史、专业经验以及技术,将彰显其作为“一带一路”倡议沿线国家中极具价值的矿业项目的地位。

The Belt and Road Initiative will have a major impact on the mining industry over the next 10 years

 The Belt and Road Initiative creates a US$5 trillion infrastructure spending spree that spans over 68 countries across Asia, the Middle East, Europe, and Africa.  Billions will be spent on ports, roads, railways, power plants, and will serve as an ongoing stimulus for commodities such as iron ore, coal, copper, crude oil and minor metals.

Citigroup Inc. reported the Belt and Road Initiative is backed by about US$900 billion worth of investments and has the potential to generate about 120 million tons of crude steel demand. This number is more optimistic to 150 million tons according to BHP published report in 2017.

Rani Jarkas, Chairman of Cedrus Investments, also commented during an interview by CNBC that the Belt and Road Initiative now is at the initial stage and has been starting to bring a huge demand boost for steel and iron ore.

This represents a great opportunity for international businesses to supply, support and partner with Chinese and other international mining companies as this massive development takes shape. For example, Australian mining businesses have experience, expertise and technology garnered from their mining industry across a very large country will prove valuable mining projects along the BRI.

CNBC interview – The opportunities for mining in the Belt and Road initiative

6 April 2018 – CNBC interview – The opportunities for mining in the Belt and Road initiative

 

CEDRUS INVESTMENTS’ CHAIRMAN MR. RANI JARKAS INVITED TO SPEAK AT THE 121 OIL & GAS INVESTMENT CONFERENCE IN HONG KONG ON THE BELT & ROAD INITIATIVE

The Chairman of Cedrus Investments (“Cedrus”), Mr. Rani Jarkas, is invited to speak at the 121 Oil & Gas Investment conference to be held on 2nd – 3rd May 2018 in Hong Kong. The event has been served as a platform for leading energy companies and sophisticated investors worldwide to network and interact, thus potentially creating more investment and development opportunities for all participants alike.

Mr. Rani Jarkas will be sharing with executives of participating oil & gas companies as well as elite investors his thoughts on investment opportunities pertaining to China’s Belt and Road initiative, aiming at exploiting new regional focuses in addition to broader markets where oil & gas companies and investors could collaborate to incentivize further growth in the oil & gas industry overall.

Mr. Rani Jarkas said, “The Belt and Road Initiative direct oil & gas companies and investors to a new geographical area for investment and helps form a link among countries in the region based on oil & gas development. Through the combination of incoming capital and technology with local resources, vast investment opportunities could be created to invigorate and further upgrade the oil & gas industry in that area, and likely bring considerable financial benefits to involved companies and investors, especially when many countries along the ancient Silk Road routes are abundant with oil and gas reserves. What Cedrus has been doing is to assist industry participants to identify the potentially most-rewarding investment opportunities based on our local knowledge and network accumulated through continued involvement in projects in Belt and Road countries as well as our deep industry expertise.”

About Cedrus Investments

Cedrus Investments is a global boutique investment firm that offers expertise in private wealth management, asset management and financial advisory services to a clientele of leading institutional investors, corporations, family offices and high net worth individuals around the world.

SOURCE Cedrus Investments

http://www.cedrusinvestments.com/pdf/news/Cedrus%20Chairman%20Invited%20to%20Speak%20at%20the%20121%20Oil%20and%20Gas%20Investment%20Hong%20Kong%202018.pdf

For further information about Cedrus Investments, please visit www.cedrusinvestments.com.

Media Enquiry:

Cedrus Investments Ltd.

Amy Sin

+852-3519-2828

information@cedrusinvestments.com

Cedrus Investments’ Chairman Mr. Rani Jarkas is Invited to Speak at the Hong Kong Biotech Invest and Partnering 2018

The Chairman of Cedrus Investments (“Cedrus”) Mr. Rani Jarkas is invited as the keynote speaker at the Asian Investment Series of the Hong Kong Biotech Invest & Partnering 2018 conference to be held on March 13, 2018, in Hong Kong. Cedrus has been participating and speaking at this annual event in Hong Kong, organized by AusBiotech (Australia’s biotechnology organization), since its inception in 2013 to foster investments in the life sciences industry across borders.

In recent years, the Asian Investment Series has expanded further to holding an annual conference in Shanghai, which is one of the hubs of life sciences investments in Asia. These conferences have brought together hundreds of Australian life sciences companies together with Hong Kong and Chinese life sciences investors where opportunities of cross-border collaborations are explored, for instance, to tap into the world’s second-largest biopharma market – China.

Mr. Jarkas will be sharing his extensive experience and profound insights, as well as Cedrus’ expertise in life sciences investment, and explaining why overseas life sciences companies should be using Hong Kong as the gateway for establishing their presence in Mainland China through joint ventures, licensing partnerships, strategic alliances or other initiatives onshore.

Mr. Jarkas said, “China is now committed to transforming the domestic life sciences industry into a global leader. For example, in recent years, we have seen growing interest from Chinese enterprises and investors to acquire life sciences technologies and products overseas to enhance China’s market position, and the increased desire of Australian life science companies to build a local presence in China. In this regard, Cedrus has competitive advantages. Through facilitating various deals, Cedrus has accumulated a lot of expertise and valuable experience in cross-border transactions and collaborations. We fully understand the potential sensitivity issues, apparent and hidden, involved in life sciences transactions across borders; hence, we can likely prevent companies from entering into unfavorable collaborations long term. In addition, we understand how to protect the companies’ assets such as intellectual properties, monetize their assets and maximize value, coupled with helping them to achieve their financial and business targets while minimizing business risks.”

About Cedrus Investments

Cedrus Investments is a global boutique investment firm that offers expertise in private wealth managementasset management and financial advisory services to a clientele of leading institutional investors, corporations, family offices and high net worth individuals around the world.

For further information about Cedrus Investments, please visit http://www.cedrusinvestments.com.

Media Enquiry:
Cedrus Investments Ltd.
Amy Sin
+852-3519-2828
information@cedrusinvestments.com

 

Source from:

http://www.cedrusinvestments.com/pdf/news/Cedrus%20Chairman%20Invited%20to%20Speak%20at%20the%20Hong%20Kong%20Biotech%20Invest%20&%20Partnering.pdf

 

 

NOVOGEN TO ESTABLISH CHINA ENTITY TO FURTHER COMMERCIALISATION AND PARTNERSHIPS IN WORLD’S SECOND-LARGEST PHARMACEUTICAL MARKET

NOVOGEN TO ESTABLISH CHINA ENTITY TO FURTHER COMMERCIALISATION AND PARTNERSHIPS IN WORLD’S SECOND-LARGEST PHARMACEUTICAL MARKET

Sydney, 13 November 2017 – Novogen Ltd (ASX: NRT; NASDAQ: NVGN), an Australian oncology drug development company, announces today that it has entered into a Letter of Intent with Cedrus Investments Ltd for advisory services in order to establish a corporate structure focused on expansion into the Greater China region.
Key Points
• Following initial face-to-face discussions with third parties in China, Novogen has signed Letter of Intent with Cedrus Investments, a leading specialist investment bank based in Hong Kong, for advisory services in order to establish a corporate structure and operations in the People’s Republic of China
• Novogen entity will be a Wholly Foreign Owned Enterprise (WFOE), initially with minimal infrastructure, to serve as administrative unit for China expansion
• Key objective will be to further explore partnerships and commercialization opportunities in China over a medium- to long-term horizon
• China is the world’s second-largest pharmaceutical market, with approximately US$ 116.7 billion in annual sales, and an annual growth rate of 12.4% (per QuintilesIMS Market Prognosis, October 2016)
The new corporate entity will enable Novogen to interact directly with the Chinese Food and Drug Administration (CFDA) for future clinical trials of its pipeline in China, and will facilitate potential partnering and investing opportunities for the company.
The Letter of Intent defines the key terms of the proposed establishment, with most of the work expected to be conducted in the first half of calendar 2018, subject to execution of definitive agreements. It is expected that the Chinese entity will be a Wholly Foreign Owned Enterprise (WFOE), headquartered in Shanghai.
Novogen CEO, Dr James Garner, commented, “China is a key market for pharmaceutical companies, and over the last few months we have been actively exploring opportunities to engage with Chinese companies, researchers, and investors to support the development of Novogen’s current and future pipeline there. The team at Cedrus Investments have been helping global companies best position themselves to identify and work with investors and business partners in the Greater China region, and are highly experienced in navigating the complex regulatory requirements in China. We are pleased to be working with them on this important project. The new corporate structure will put us in a stronger position to capitalize on opportunities in China over the medium term.”
In addition to its Australian operations and the intended China operation, Novogen also has a US-based corporate entity, Novogen North America, Inc.